Detrimental impacts and QSAR baseline toxicity assessment of Japanese medaka embryos exposed to methylparaben and its halogenated byproducts

Despite the theoretical risk of forming halogenated methylparabens (halo-MePs) during water chlorination in the absence or presence of bromide ions, there remains a lack of in vivo toxicological assessments on vertebrate organisms for halo-MePs. This research addresses these gaps by investigating the lethal (assessed by embryo coagulation) or sub-lethal (assessed by hatching success/heartbeat rate) toxicity and teratogenicity (assessed by deformity rate) of MeP and its mono- and di-halogen derivatives (Cl- or Br-) using Japanese medaka embryos. In assessing selected apical endpoints to discern patterns in physiological or biochemical alterations, heightened toxic impacts were observed for halo-MePs compared to MeP. These include a higher incidence of embryo coagulation (4-36 fold), heartbeat rate decrement (11-36 fold), deformity rate increment (32-223 fold), hatching success decrement (11-59 fold), and an increase in Reactive Oxygen Species (ROS) level (1.2-7.4 fold)/Catalase (CAT) activity (1.7-2.8 fold). Experimentally determined LC50 values are correlated and predicted using a Quantitative Structure Activity Relationship (QSAR) based on the speciation-corrected liposome-water distribution ratio (Dlipw, pH 7.5). The QSAR baseline toxicity aligns well with (sub)lethal toxicity and teratogenicity, as evidenced by toxic ratio (TR) analysis showing TR < 10 for MeP exposure in all cases, while significant specific or reactive toxicity was found for halo-MeP exposure, with TR > 10 observed (excepting three values). Our extensive findings contribute novel insights into the intricate interplay of embryonic toxicity during the early-life-stage of Japanese medaka, with a specific focus on highlighting the potential hazards associated with halo-MePs compared to the parent compound MeP.

Characterization of pregnant women exposure to halogenated parabens and bisphenols through water consumption

Exposure of pregnant women to endocrine disruptor compounds, such as parabens and bisphenol A is of concern for fetal transition. Their halogenated degradation products, mainly coming from water treatment plans, could be problematic as well, depending on their occurrence in drinking water in the first place. Thus, 25 halogenated compounds were synthesised in order to investigate 60 substances (Bisphenols, parabens and their degradation products) in 325 drinking water samples coming from a French cohort study of pregnant women. Analysis was performed by tandem mass spectrometry coupled to gas chromatography (GC-MS/MS) after SPE extraction and derivation of the contaminants. Results indicate that parabens (methylparaben, n-propylparaben, ethylparaben and n-butylparaben), bisphenols S, A and F, and their degradation product, 4-hydroxybenzoic acid, were detected up to several hundred ng/L in drinking water, with detection frequencies between 16% and 88%. Regarding halogenated degradation products, the highest detection frequencies were found for monochlorinated products (about 50% for 2-chlorobisphenol A), which were quantified up to several tens of ng/L. Such analytical approaches with broader spectrum of monitoring (i.e. chemical hazards and their degradation products) constitute in the beginning of a solution to exhaustively answer the questions related to the characterization of the human chemical exposome.

Halogenated ingredients of household and personal care products as emerging endocrine disruptors

The everyday use of household and personal care products (HPCPs) generates an enormous amount of chemicals, of which several groups warrant additional attention, including: (i) parabens, which are widely used as preservatives; (ii) bisphenols, which are used in the manufacture of plastics; (iii) UV filters, which are essential components of many cosmetic products; and (iv) alkylphenol ethoxylates, which are used extensively as non-ionic surfactants. These chemicals are released continuously into the environment, thus contaminating soil, water, plants and animals. Wastewater treatment and water disinfection procedures can convert these chemicals into halogenated transformation products, which end up in the environment and pose a potential threat to humans and wildlife. Indeed, while certain parent HPCP ingredients have been confirmed as endocrine disruptors, less is known about the endocrine activities of their halogenated derivatives. The aim of this review is first to examine the sources and occurrence of halogenated transformation products in the environment, and second to compare their endocrine-disrupting properties to those of their parent compounds (i.e., parabens, bisphenols, UV filters, alkylphenol ethoxylates). Albeit previous reports have focused individually on selected classes of such substances, none have considered the problem of their halogenated transformation products. This review therefore summarizes the available research on these halogenated compounds, highlights the potential exposure pathways, and underlines the existing knowledge gaps within their toxicological profiles.

Assessment of the endocrine-disrupting potential of halogenated parabens: An in silico approach

Parabens are endocrine-disrupting chemicals present in a variety of pharmaceutical and personal care products. Due to their wide-spread use, significant amounts are also released into the aquatic domain of the environment. During water disinfection, parabens give rise to halogenated transformation products. As opposed to parabens, there is considerable lack of knowledge with regard to the endocrine-disrupting potential of their halogenated counterparts, which presents a challenge for regulatory decision making. We aimed to fill this knowledge gap by using the Endocrine Disruptome and VirtualToxLab™ to predict their endocrine-disrupting potential on the basis of calculated affinities for different nuclear receptors. The applied computational approach indicates a high probability of halogenated parabens binding to glucocorticoid, thyroid and aryl hydrocarbon receptors and suggests that disinfection is likely to form transformation products with more pronounced endocrine-disrupting activities than those of parent parabens. The obtained results not only highlight the need for additional in vitro/in vivo investigations of these chemicals as endocrine disruptors but also provide a means of guiding and prioritizing these future studies, in order to assess fully their hazard to human health.

Prioritizing selected PPCPs on the basis of environmental and toxicogenetic concerns: A toxicity estimation to confirmation approach

Pharmaceuticals and personal care products (PPCPs), the pollutants of emerging concerns, present potential risks to the ecological environment. This study focused on the prioritization of widely used selected PPCPs belonging to two categories:personal care products (PCPs) and non-steroidal anti-inflammatory drugs (NSAIDs). We predicted the toxicogenetic endpoints of PPCPs and then confirmed them using experimental approaches. Our results revealed a significant similarity in the findings obtained through both approaches, indicating NSAIDs with relatively high environmental impacts and in vitro/vivo toxicity. Experimental approach revealed that musk xylene (MX) from PCPs and DIC from NSAIDs as individual chemicals of priority concern showed elevated environmental impacts and significantly induced pi3k-akt-mTOR in vitro. Similarly, propyl paraben (PP) from PCPs and diclofenac (DIC) from NSAIDs caused significant cytotoxicity and DNA damage in vitro. Moreover, PP and MX from the PCPs group and naproxen (NAP) and DIC from the NSAIDs group induced developmental toxicity and perturbations to phases I, II, and III detoxification pathways in vivo. In addition, MX and DIC as priority PPCPs inhibited hematopoiesis and hepatogenesis in vivo. Apart from the specific effects, PPCPs can be ranked as: MX > PP > methylparaben (MP) for PCPs, and DIC > NAP > ibuprofen (IBU) for NSAIDs, regarding their toxic and environmental concerns.

Estrogen agonistic/antagonistic activity of brominated parabens

The estrogen agonistic/antagonistic activity of 16 brominated by-products of parabens was assessed by using a yeast two-hybrid assay transfected with the human estrogen receptor α. Characterization of synthetic compounds including novel brominated parabens was performed using ¹H-NMR spectroscopy and high-resolution mass spectrometry. For the agonist assay, five C₃-C₄ alkylparabens exhibited significant activity (P < 0.05) relative to that of 17β-estradiol, ranging from 3.7 × 10^-5 to 7.1 × 10^-4. In contrast, none of the brominated alkyl parabens exhibited agonistic activity. In the antagonist assay, 12 brominated alkylparabens and butylparaben exhibited significant antagonistic activity (P < 0.05). Their antagonistic activity relative to 4-hydroxytamoxifen ranged from 0.11 to 2.5. The antagonist activity of C₁-C₄ alkylparabens increased with the number of bromine substitutions. Benzylparaben exhibited both agonistic and antagonistic activity, and these activities dissipated or were weakened with increased bromination. Thus, increased bromination appeared to attenuate the estrogen agonistic activity of most parabens such that it resulted in increased antagonistic activity, a feature of parabens that had not been previously described.